.png){kind=icon}
返回
.png){kind=icon}
.png){kind=icon}
摘要
En 中文
Finerenone (Kerendia(R)), a first-in-class, orally administered, selective, nonsteroidal mineralocorticoid receptor antagonist (MRA), is being developed by Bayer HealthCare Pharmaceuticals for the treatment of diabetic kidney disease (DKD) and heart failure (HF), including chronic HF (CHF). Finerenone has been approved in the USA to reduce the risk of sustained estimated glomerular filtration rate (eGFR) decline, end stage renal disease (ESRD), cardiovascular death, nonfatal myocardial infarction (MI), and hospitalization for HF in adults with chronic kidney disease (CKD) associated with type 2 diabetes (T2D). Finerenone is undergoing regulatory assessment in the EU and in China. A phase III trial is investigating finerenone in patients who have HF with preserved ejection fraction. This article summarizes the milestones in the development of finerenone leading to this first approval to reduce the risk of serious kidney and heart complications in adults with CKD and T2D.
Keyword:
CHRONIC HEART-FAILURE
MINERALOCORTICOID RECEPTOR ANTAGONISM
BASE-LINE CHARACTERISTICS
TYPE-2 DIABETES-MELLITUS
CHRONIC KIDNEY-DISEASE
BAY 94-8862
VS. EPLERENONE
JAPANESE PATIENTS
DESIGN
TOLERABILITY
期刊
IF:
14.4
论文数:
8.4K
被引数:
2.3W
机构
暂无机构信息
引用论文
The alpha 3 chain of type IV collagen prevents activation of human polymorphonuclear leukocytes..png)
OAAI
OAAI.png){kind=icon}
分享.png){kind=icon}
收藏
Selective Mineralocorticoid Receptor Cofactor Modulation as Molecular Basis for Finerenone's Antifibrotic Activity.png)
HYPERTENSIONOAAI
HYPERTENSIONIF8.2
OAAI分享收藏分享收藏
查看更多内容